Literature DB >> 31002129

HCP5 promotes colon cancer development by activating AP1G1 via PI3K/AKT pathway.

W-K Yun1, Y-M Hu, C-B Zhao, D-Y Yu, J-B Tang.   

Abstract

OBJECTIVE: To explore whether HCP5 participates in the pathogenic progression of colon cancer (CC) and its underlying mechanism. PATIENTS AND METHODS: HCP5 expression in CC tissues and cell lines was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between the HCP5 expression and tumor stage of CC patients was then analyzed. After CC cells were transfected with HCP5-siRNA, the proliferation and migration capacities were detected by cell counting kit-8 (CCK-8), colony formation and transwell assay, respectively. Cell cycle was examined by flow cytometry. Western blot was conducted to detect protein expressions of HCP5, AP1G1 and relative molecules in the PI3K/AKT pathway. Rescue experiments were performed by co-transfection of HCP5-siRNA and AP1G1-siRNA into CC cells, followed by cell function detection.
RESULTS: HCP5 was highly expressed, whereas AP1G1 was lowly expressed in CC tissues and cell lines. Besides, CC patients with stage III-IV presented higher expression of HCP5 than those with stage I-II. The knockdown of HCP5 in CC cells down-regulated proliferation and migration capacities, and arrested cell cycle in the G0/G1 phase, which was reversed by the AP1G1 knockdown. In addition, HCP5 knockdown up-regulated AP1G1 expression, whereas down-regulated the expression of relative proteins in the PI3K/AKT pathway.
CONCLUSIONS: HCP5 was significantly increased in CC and enhanced the proliferation and migration of CC cells by inhibiting the AP1G1 expression. HCP5 promoted CC development by activating the PI3K/AKT pathway.

Entities:  

Year:  2019        PMID: 31002129     DOI: 10.26355/eurrev_201904_17553

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  LncRNA HCP5 Promotes Cell Invasion and Migration by Sponging miR-29b-3p in Human Bladder Cancer.

Authors:  Cheng Zhao; Yangle Li; Xiheng Hu; Ruizhe Wang; Wei He; Long Wang; Lin Qi; Shiyu Tong
Journal:  Onco Targets Ther       Date:  2020-11-17       Impact factor: 4.147

2.  LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.

Authors:  Qinhua Liu; Ruonan Ran; Mingyue Song; Xiaodan Li; Zhengsheng Wu; Guanrong Dai; Ruixiang Xia
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

3.  LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.

Authors:  Jianyu Xu; Jianli Ma; Bixi Guan; Jian Li; Yan Wang; Songliu Hu
Journal:  Cell Cycle       Date:  2021-06-30       Impact factor: 5.173

Review 4.  Long Noncoding RNA HCP5, a Hybrid HLA Class I Endogenous Retroviral Gene: Structure, Expression, and Disease Associations.

Authors:  Jerzy K Kulski
Journal:  Cells       Date:  2019-05-20       Impact factor: 6.600

5.  TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.

Authors:  Dan-Hong Huang; Jie Jian; Shuang Li; Yan Zhang; Li-Zhen Liu
Journal:  Int J Mol Med       Date:  2019-10-14       Impact factor: 4.101

6.  Effects of LncRNA HCP5/miR-214-3p/MAPK1 Molecular Network on Renal Cell Carcinoma Cells.

Authors:  Jun-Feng Hao; Pei Chen; He-Yi Li; Ya-Jing Li; Yu-Ling Zhang
Journal:  Cancer Manag Res       Date:  2020-12-24       Impact factor: 3.989

Review 7.  LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis.

Authors:  Shao-Pu Hu; Meng-Xue Ge; Lei Gao; Min Jiang; Kai-Wen Hu
Journal:  Cancer Cell Int       Date:  2021-12-19       Impact factor: 5.722

8.  De novo and bi-allelic variants in AP1G1 cause neurodevelopmental disorder with developmental delay, intellectual disability, and epilepsy.

Authors:  Muhammad A Usmani; Zubair M Ahmed; Pamela Magini; Victor Murcia Pienkowski; Kristen J Rasmussen; Rebecca Hernan; Faiza Rasheed; Mureed Hussain; Mohsin Shahzad; Brendan C Lanpher; Zhiyv Niu; Foong-Yen Lim; Tommaso Pippucci; Rafal Ploski; Verena Kraus; Karolina Matuszewska; Flavia Palombo; Jessica Kianmahd; Julian A Martinez-Agosto; Hane Lee; Emma Colao; M Mahdi Motazacker; Karlla W Brigatti; Erik G Puffenberger; S Amer Riazuddin; Claudia Gonzaga-Jauregui; Wendy K Chung; Matias Wagner; Matthew J Schultz; Marco Seri; Anneke J A Kievit; Nicola Perrotti; J S Klein Wassink-Ruiter; Hans van Bokhoven; Sheikh Riazuddin; Saima Riazuddin
Journal:  Am J Hum Genet       Date:  2021-06-07       Impact factor: 11.025

9.  lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.

Authors:  Shibo Zou; Ya Gao; Shutang Zhang
Journal:  Int J Oncol       Date:  2021-07-01       Impact factor: 5.650

10.  HCP5, as the sponge of miR-1291, facilitates AML cell proliferation and restrains apoptosis via increasing PIK3R5 expression.

Authors:  Yan Liu; Xue-Bing Jing; Zhen-Cheng Wang; Qing-Kun Han
Journal:  Hum Genomics       Date:  2021-06-29       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.